Tango Therapeutics TNGX Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's total cash, cash equivalents, and restricted cash (inclusive)?
- Tango Therapeutics (TNGX) reported total cash, cash equivalents, and restricted cash (inclusive) of $159.97M in Q1 2026.
- How has Tango Therapeutics's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Tango Therapeutics's total cash, cash equivalents, and restricted cash (inclusive) increased by 162.2% year-over-year, from $61M to $159.97M.
- What is the long-term trend for Tango Therapeutics's total cash, cash equivalents, and restricted cash (inclusive)?
- Over 5 years (2020 to 2025), Tango Therapeutics's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 30.2% compound annual growth rate (CAGR), from $30.66M to $114.85M.